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Background: Lyme disease accounts for .90% of all vector-borne disease cases in the United 
States and affects  ~300,000 persons annually in North America. Though traditional tetracycline 
antibiotic therapy is generally prescribed for Lyme disease, still 10%–20% of patients treated 
with current antibiotic therapy still show lingering symptoms.
Methods: In order to identify new drugs, we have evaluated four cephalosporins as a therapeutic 
alternative to commonly used antibiotics for the treatment of Lyme disease by using microdilution 
techniques like minimum inhibitory concentration (MIC) and the minimum bactericidal concentration 
(MBC). We have determined the MIC and MBC of four drugs for three Borrelia burgdorferi s.s strains 
namely CA8, JLB31 and NP40. The binding studies were performed using in silico analysis.
Results: The MIC order of the four drugs tested is cefoxitin (1.25 µM/mL) . cefamandole 
(2.5 µM/mL), . cefuroxime (5 µM/mL) . cefapirin (10 µM/mL). Among the drugs that are tested 
in this study using in vivo C3H/HeN mouse model, cefoxitin effectively kills B. burgdorferi. The 
in silico analysis revealed that all four cephalosporins studied binds effectively to B. burgdorferi 
proteins, SecA subunit penicillin-binding protein (PBP) and Outer surface protein E (OspE).
Conclusion: Based on the data obtained, cefoxitin has shown high efficacy killing B. burgdorferi 
at concentration of 1.25 µM/mL. In addition to it, cefoxitin cleared B. burgdorferi infection in 
C3H/HeN mice model at 20 mg/kg.
Keywords: Lyme disease, Borrelia burgdorferi, antimicrobials, penicillin-binding proteins
Introduction
Lyme disease is the most common zoonotic bacterial disease in North America. More 
than 300,000 cases of clinical Borreliosis are reported annually in the United States 
alone.1 Though Lyme disease has been prevalent in the colder regions for decades, 
many new cases have been emerging in the warmer regions of United States where 
there had been no earlier reports. This increase in the biogeographical distribution of 
the disease is mainly attributable to the climate change and ability of the pathogenic 
agent and disease vector to survive in varying biologic and geographical conditions.2,3 
Among humans, there are a number of clinical presentations of disease including 
erythema migrans, fever, chills, and muscle and joint pain.4 Though these symptoms 
tend to fade away even if there is no therapeutic intervention, a significant number of 
untreated patients tend to develop arthritis and persistent myalgia over months to years 
following the exposure to Borrelia.5 More than 10% of the patients who have been 
treated for Lyme disease tend to develop symptoms considered typical or even exag-
gerated presentation of Lyme disease including muscle and joint pain and generalized 
fatigue.6,7 This condition is referred to as posttreatment Lyme disease syndrome.8,9
Amoxicillin, doxycycline, cefuroxime axetil, and ceftriaxone are currently considered 
the drugs of choice for the treatment of the Lyme disease.10 Even though the drugs used 
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in the current treatment are clinically effective in the majority 
of cases, treatment failures have been repeatedly reported for 
most of these compounds.9,11,12 Though a number of therapeutic 
interventions have been used for Lyme disease treatment, yet the 
reappearance of clinical symptoms of the disease even after the 
active disease has subsided calls for efforts for identifying novel, 
potent alternate therapeutic strategies. Some researchers have 
showed that Borrelia burgdorferi (Bb) cannot be eliminated 
completely in in vitro cultures.13,14 Antibiotic-tolerant Borrelia 
cells shown in these studies are not resistant mutants but per-
sisters. The currently prescribed drugs used for treating Lyme 
disease were also not able to eliminate the Bb completely.13
Cephalosporins can be used as an alternative therapy to 
non-tetracycline antimicrobials.11,15 Cephalosporins are safe 
enough to be used as an alternative treatment for Lyme disease 
in children and during pregnancy when doxycycline cannot be 
administered because of detrimental side effects.15,16 β-lactams 
bind to penicillin-binding proteins (PBPs), which are cytoplas-
mic membrane-associated enzymes that catalyze terminal reac-
tions in the biosynthesis of peptidoglycan.17,18 The enzyme PBPs 
are targeted by β-lactams and disrupt various functions like cell 
growth, cell division, and the maintenance of cell shape.19 In Bb, 
β-lactam compounds bind to outer surface protein A (OspA), 
OspB, and OspD, which are considered to be types of PBPs.20
This study aims at determining the in vitro susceptibility 
of Bb s.s. strains to the four cephalosporins. Furthermore, the 
in vivo efficacy for the candidate drug cefoxitin in C3H/HeN 
mouse model was also determined. The interaction of the 
four cephalosporins against SecA subunit PBP and OspE was 
evaluated by in silico analysis. It was found that all the cepha-
losporins showed high binding affinity to the essential PBP.
Materials and methods
Bacterial strains and culture
Three strains of Bb s.s (CA8, JLB31, and NP40) of low passage 
number were cultured in Barbour-Stoenner-Kelly II (BSK-II) 
complete medium supplemented with 6% rabbit serum (Sigma, 
St Louis, MO, USA). The cultures were grown in 50 mL falcon 
tubes (Corning Inc, Corning, NY, USA) at 33°C for 3–5 days 
in a 5% CO
2
 incubator. The BSK-II medium was sterilized 
through 0.2 µm filter units (Millipore, Billerica, MA, USA). 
The bacterial strains JLB31 and NP40 were generously pro-
vided by Dr Linden Hu, Tufts University, Boston, MA, USA.
Minimum inhibitory concentration (Mic) 
and minimum bactericidal concentration 
(MBc)
The MIC and MBC values of the seven antimicrobials 
were determined by microdilution techniques. MIC was 
determined by culturing 106/mL Bb in BSK-II medium 
with different concentrations of drugs ranging from 0.31 to 
160 µM. For the MIC, the 1 mL cultures were grown in 
48-well plates in triplicates, wrapped with parafilm, and 
placed in the incubator for 72 hours at 33°C in a humidi-
fied 5% CO
2
 incubator (Forma Scientific, USA).21,22 The 
MIC was determined by using Bac Titer-Glo microbial 
cell viability assay. After 72 hours, 100 µL of culture 
was taken from each well and mixed with 100 µL of Bac 
Titer-Glo® reagent (Promega, Madison, WI, USA). Then, 
the assay was performed according to the manufacturer’s 
instructions. Luminescence was measured on a Flex Sta-
tion 3 micro plate reader at an integration time of 500 
milliseconds.21
Conversely, for determining MBC, 106/mL Bb cultures 
grown in BSK-II medium for 72 hours at different drug 
concentrations were centrifuged and the supernatant was 
removed. Five hundred microliters of the fresh BSK-II 
medium was added to the pellet, and resuspended, to which 
100 µL was added to fresh 1 mL BSK-II medium and sub-
cultured for 3 weeks. After 3 weeks of incubation period, 
the samples were observed microscopically for motile 
spirochetes in the culture. Cell proliferation was assessed 
using a bacterial counting chamber (Petroff-Hausser Coun-
ter, Horsham, PA, USA) by phase contrast microscopy. The 
procedure was replicated thrice.15,21–23
Mice
Four-week-old female C3H/HeN mice were purchased from 
Charles River Laboratories, Wilmington, MA, USA. All 
mice were maintained in the pathogen-free animal facility 
according to animal safety protocol guidelines at Stanford 
University under the protocol ID APLAC-30105. All exper-
iments were in accordance with the protocols approved by 
the Institutional Animal Care and Use Committee of Stan-
ford University. The mice were infected intradermally with 
0.1 mL BSK medium containing 100,000 Bb organisms. 
On the seventh day of infection, the mice were intrap-
eritoneally administered a daily dose of drugs, cefoxitin 
(20 mg/kg) and ceftriaxone (50 mg/kg) for five consecu-
tive days. After 48 hours of the last dose of administering 
compounds, the mice were killed and their urinary blad-
ders, ears, and hearts were suspended in BSK-II medium. 
The cultures were evaluated for the presence of motile 
spirochetes after 21 days using the dark-field microscopy.24 
If Bb was observed in any one of the organ in the mice, the 
animal was considered as infected. The absence of borrelial 
propagation marked the effectiveness of the treatment in 
these organisms.
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Molecular docking
The potential binding affinity and binding modes of the test com-
pounds were determined by performing a molecular docking 
study. For this purpose, two membrane-associated proteins 
were selected as mentioned in Table 3. The protein structures 
were either retrieved from the Protein Data Bank or deter-
mined by ab initio molecular modeling using the Phyre 2 
Server. The ligand molecules were prepared using Chem-
Sketch and then docking specifically against the Bb proteins 
using AutoDock Vina (v.1.1.2) through a validated docking 
protocol.18,25 The binding affinity of the test compounds to the 
proteins expressed in kcal/mol was obtained. The binding modes 
were visualized in Discovery Studio 4.0 (Accelrys, USA).26
Results
Determination of Mic and MBc values
The in vitro susceptibility of these drugs to three strains CA8, 
JLB31, and NP40 of Bb was evaluated by using BacTiter-
Glo Assay and microscopy. Based on the MICs obtained 
the in vitro efficacy of the tested molecules was arranged in 
the following order for NP40 strain of Bb: cefoxitin (MIC: 
1.25 µM/mL) .cefamandole (MIC: 2.5 µM/mL), .cefu-
roxime (MIC: 5 µM/mL) .cefapirin (MIC: 10 µM/mL). Also, 
the in vitro efficacies of tested molecules for other two strains 
are as follows, for CA8 strain of Bb: cefoxitin (MIC: 0.625 µM/
mL) .cefuroxime (MIC: 1.25 µM/mL), .cefamandole (MIC: 
1.25 µM/mL) .cefapirin (MIC:5.0 µM/mL) and for JLB31 
strain of Bb: cefoxitin (MIC: 0.625 µM/mL) .cefuroxime 
(MIC: 1.25 µM/mL), .cefamandole (MIC: 1.25 µM/mL) 
.cefapirin (MIC: 2.5 µM/mL). These results indicate that 
for the JLB31 and CA8 strains cefoxitin was more effective 
(MIC: 0.625 µM/mL) than NP40 strain (MIC: 1.25 µM/mL). 
The efficacy of cephalosporins (tested compounds) was deter-
mined by BacTiter-Glo Assay as shown in Figure 1. Similarly, 
we determined the MBC of all the tested cephalosporins. The 
MBC values of cefoxitin and cefuroxime were #10 µM. 
Cefamondole showed MBC value #20 µM. For cefapirin, 
the MBC value was very high for NP40 (.160 µM) but for 
other strains it was #20 µM. The MIC and MBC values of 
the tested compounds against the three Bb strains have been 
provided in Table 1. Based on these in vitro analyses, cefoxitin 
was the most potent compound among these cephalosporins 
tested in our laboratory. We proceeded further for mouse 
efficacy experiments to provide a better correlation to the 
clinical conditions.
in vivo testing of drugs in c3h/hen mice
The efficacies of drugs cefoxitin and gambogic acid were 
tested in 5–6-week-old female C3H/HeN mice. One week 
after the Bb infection (1×105 of Bb intradermal route), mice 
were treated with cefoxitin once a day for 5 days. The mice 
were killed and the collected organs, ear, urinary bladder, and 
heart, were placed in BSK-II medium. The tissue samples 
(ear, urinary bladder, and heart) found no detectable Bb in all 
the mice treated with cefoxitin. Cefoxitin cleared infection in 
all the mice at 20 mg/kg (Table 2). In ceftriaxone, which was 
used as a positive control, no borrelial growth was observed. 
Bb growth was observed in control saline samples treated 
with no drug. The efficacy of the drugs tested in vivo has 
been shown in Table 2.
in silico analysis of cephalosporins binding 
to PBPs and Osps
Computational analysis was performed in order to determine 
the binding potential of the candidate molecules against the 
Bb proteins listed in Table 3. Previous studies have identified 
Figure 1 The efficacy of cephalosporins determined by BacTiter-Glo Assay.
Notes: effect of drugs on Borrelia cell viability was studied with drugs (cefoxitin, 
cefamandole, cefuroxime, and cefapirin) on ca8 strain. The control has no drug. 
The results represent mean ± sD.
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Table 1 Mic and MBc values (in µM) of the tested compounds 
on bacterial strains ca8, JlB31, and nP40
Compounds CA8 JLB31 NP40
MIC values
cefamandole 1.25 1.25 2.5
cefapirin 2.5 5 10
cefoxitin 0.625 0.625 1.25
cefuroxime 1.25 2.5 5
MBC values
cefamandole 20 40 20
cefapirin 20 10 .160
cefoxitin 5 5 2.5
cefuroxime 10 20 10
Abbreviations: MBc, minimum bactericidal concentration; Mic, minimum 
inhibitory concentration.
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that β-lactam antibiotics bind covalently with PBPs and 
Osps, and they exert their antibacterial effect by blocking 
the terminal step in cell wall biosynthesis.17,27 Based on these 
previous studies, we performed binding studies between 
cephalosporin drugs (cefamandole, cefapirin, cefoxitin, and 
cefuroxime) and SecA subunit PBP and OspE. The binding 
affinities (docking scores) of PBP and OspE with the four 
cephalosporins are listed in Table 3.
The molecular docking study revealed that among the 
drug molecules cefamandole possessed the highest binding 
affinity (-8.4 kcal/mol) for the SecA subunit PBP of Bb. The 
average binding affinity values (-7.9 kcal/mol) against the test 
compounds for PBP was significantly higher than the other 
Borrelia proteins. The cefoxitin that was tested and effective 
in mice showed a strong binding affinity of -7.2 kcal/mol 
for PBP. It shows a strong hydrogen bonding at amino 
acid Arg138 of PBP of Borrelia, with an intermolecular 
distance of less than 5 Å indicating a high preference for 
this protein. It also forms other interactions like 9 Van der 
Waals, Pi Stacking, and Alkyl type (Table 4). Other com-
pounds including cefapirin (-7.9 kcal/mol) and cefuroxime 
(-8.2 kcal/mol) also interacted with the drug-binding pockets 
of the PBP of Borrelia effectively with no statistically sig-
nificant difference between the values. The linear and spatial 
arrangement of the four cephalosporins with PBP has been 
provided in Figure 2. All the interactions predicted between 
cephalosporins and PBP can be found in Table 4.
Discussion
We have chosen four cephalosporins (cefoxitin, cefaman-
dole, cefuroxime, and cefapirin) in this study based on the 
results obtained in the high-throughput screening we have 
performed.23,28 In this study, to our knowledge for the first 
time, in vitro susceptibility of three Bb s.s. strains (CA8, 
JLB31, and NP40) against cephalosporins was determined. 
Microdilution-based methods have been extensively studied 
in various groups.22 Using similar method we tested cepha-
losporins, and cefoxitin, a second-generation cephalosporin, 
was found to be one of the most potent drugs that significantly 
inhibited the cell wall synthesis of Borrelia.15,22 Cefamandole, 
cefapirin, and cefuroxime also effectively inhibited the 
propagation of the spirochete. The MBC determined for Bb 
strain NP40 was higher than 160 µM to the antimicrobial 
agent cefapirin. Some of the potential explanations for a high 
MBC might be decreased in vitro activity of cefapirin due 
to the unstable β-lactam ring, which results in decreasing 
concentrations during prolonged incubation. Another reason 
could be that cefapirin might be in bacteriostatic mode in 
NP40 strain as its MIC is also very high.29 Due to its low MIC 
and MBC values, cefoxitin was evaluated in vivo in C3H/
HeN mice model, and was able to eliminate the Bb infection 
completely. Cefoxitin is a broad-spectrum antibiotic effective 
against a wide variety of infections caused by Gram-positive 
or Gram-negative aerobes as well as by anaerobic bacteria. 
Cefoxitin is used to treat many infections like intra-abdominal 
infections, lower respiratory tract infections, urinary tract 
and gonococal infections, skin and soft-tissue infections, 
bone and joint infections, and bacteremia.30,31 Multiple fea-
tures are essential for the efficacy of an antibiotic to clear 
Bb; moreover, there is no clinical guidelines existing for 
the treatment of chronic borreliosis, and our findings are of 
immense interest and warrant further study, including in vivo 
efficacy studies.
A number of cephalosporins were found to be highly 
effective in eliminating Borrelia in both in vitro and in vivo 
evaluation.15,32 Cephalosporins, much similar to the penicil-
lins and also containing β-lactam ring, act on the cell mem-
brane of the bacteria and inhibit the peptidoglycan synthesis.17 
PBPs are one of the essential prokaryotic membrane proteins 
present in both Gram-positive and Gram-negative bacteria. 
As in other bacteria, PBPs are cytoplasmic membrane-
associated enzymes that catalyze terminal reactions in the 
biosynthesis of peptidoglycan in Borrelia. β-lactams are 
Table 2 Therapeutic effectiveness of tested compounds in 
Borrelia burgdorferi-infected c3h mice
Drug name Concentration 
of drugs
No of 
mice 
infected
No of 
mice 
treated
No of mice 
cured/no of 
mice given
cefoxitin 20 mg/kg 3 3 3/3
ceftriaxone 50 mg/kg 3 3 3/3
saline (control) 3 3 0/3
Table 3 Predicted docking scores of cephalosporins with Borrelia burgdorferi seca-PBP and Ospe
Protein name Pdb I.D. Binding affinity (kcal/mol)
Cefamandole Cefapirin Cefoxitin Cefuroxime
seca subunit PBP ab initio -8.4 -7.9 -7.2 -8.2
Ospe 2M4F -7.1 -6.2 -7.3 -7.2
Abbreviations: seca-PBP, subunit penicillin-binding protein; Ospe, outer surface protein e.
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substrate analogs of the terminal D-Ala-D-Ala residues on the 
pentapeptide cross-bridges of peptidoglycan subunits, which 
by binding to PBPs terminate peptidoglycan synthesis.20,27 It 
has been shown in many types of bacteria, as well as in Bb, 
that compounds with β-lactam ring bind to PBP.33 It has been 
shown in many types of bacteria, as well as in B. burgdorferi, 
that compounds with β-lactam ring bind to PBP.20 Based 
on these findings, we have done in silico binding studies 
between four cephalosporin drugs (cefamandole, cefapirin, 
cefoxitin, and cefuroxime) and two Bb proteins (secA-PBP 
Table 4 interaction of tested cephalosporins with Borrelia burgdorferi seca-penicillin-binding protein (seca-PBP)
Compound Binding affinity  
(kcal/mol)
Types of interaction
Strong hydrogen  
bonding
Van der Waals Pi stacking Alkyl
cefamandole -8.4 Tyr193, ile676 arg765, Tyr766
cefapirin -7.9 lys374, arg351, his358,  
glu372, Thr229
gly350, glu338, ile339, leu348, gly336,  
glu362, ala781, gln359, ser785
glu230 arg352, ala370
cefoxitin -7.2 arg138 glu524, ser489, Tyr134, Phe493,  
Val527, Thr515, lys518
Trp142, ala496, ile523
cefuroxime -8.2 ile523, asn522, Tyr134,  
glu524
Phe493, arg138, ala492, Thr515,  
ala496, lys518, gly521
Figure 2 spatial arrangement of the in silico tested cephalosporins with seca translocase PBP of Borrelia burgdorferi: (A) cefamandole, (B) cefapirin, (C) cefoxitin, and 
(D) cefuroxime.
Note: The amino acid sequence of seca-PBP (B. burgdorferi B31) was retrieved from the Uniprot KB (gene BB_0718) with a genBank gene accession number of ae000783 
(translation aac67056.2.).
Abbreviation: PBP, penicillin-binding protein.
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and OspE) shown in Table 3. The in silico analysis we per-
formed showed a high binding preference of cephalosporins 
to these proteins, further validating the targeting of these 
essential proteins by the test compounds.
This study gives a new insight into the nature of effective 
Borrelia antibiotics, and this improved understanding of the 
compound–protein interactions can be used to help find new 
targets to aid in the eradication of Borrelia. The preclinical 
data presented here are beneficial in ascertaining the effec-
tiveness of these molecules and their ability to specifically 
interact with the bacterial system without possessing any 
significant adverse effects on the host organism. The out-
come of this study can provide input for both mechanistic 
and translational research, and could be used in establishing 
clinically viable solutions to Lyme disease.
Conclusion
We have evaluated the in vitro susceptibility of four drugs 
to three strains of Bb (CA8, JLB31, and NP40) by using 
microdilution techniques. Cefoxitin (1.25 µM/mL) has shown 
low MIC and MBC values. Cefoxitin effectively cleared 
infection of Bb in the C3H/HeN mice model at 20 mg/kg. 
By in silico analysis we have shown binding affinities of 
four cephalosporins with two Bb proteins (PBP and OspE). 
The SecA subunit PBP has shown higher binding affinity 
with all the cephalosporins and has potential to study as an 
effective drug target. We are in the process of performing 
large-scale studies to prove this potential application of the 
four cephalosporins evaluated in our study.
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